Mastek: Business Overview & Financial Analysis
Mastek is an Indian multinational digital engineering, cloud transformation, and enterprise IT services enterprise headquartered in Mumbai, Maharashtra. Promoted by Ashank Desai, Paresh Shiralkar, and Sundar Radhakrishnan, the company delivers cloud migration, digital commerce, enterprise application management, and generative AI solutions. Operating across delivery hubs in India, the UK, Europe, the US, the Middle East, and Asia-Pacific, Mastek serves public sector government departments, healthcare institutions, retail brands, and financial services organizations globally.
Segment Revenue Mix of Mastek (Q1 FY2027)
Mastek structures its operational turnover across core Digital Engineering & Cloud Transformation, Oracle Cloud & Enterprise Applications, and Legacy Application Maintenance divisions.
- Digital Engineering & Cloud Transformation Share – 48.5% of Operating Revenue
- Oracle Cloud & Enterprise Applications Share – 38.2% of Operating Revenue
- Legacy Application Maintenance & Others Share – 13.3% of Operating Revenue
- Total Consolidated Revenue from Operations (Q1 FY2027) – Rs 820.50 crore (+12.4% YoY)
Digital engineering and cloud transformation services serve as the primary growth engine, driven by cloud migration contracts across UK public sector and US enterprise clients. Oracle Cloud application implementation supplies high-margin recurring integration revenue.
Geographic Revenue Breakdown of Mastek (Q1 FY2027)
The enterprise balances its IT service dispatches across the United Kingdom, North America, Middle East, and Asia-Pacific regions.
- UK & Europe Market Share – 62.5% of Total Revenue (Rs 512.80 crore)
- North America Market Share – 22.8% of Total Revenue (Rs 187.10 crore)
- Middle East & AMEA Market Share – 14.7% of Total Revenue (Rs 120.60 crore)
The UK and European region generates over six-tenths of total corporate turnover, anchored by long-standing digital transformation contracts with the UK government and National Health Service (NHS). North American operations supply enterprise retail and healthcare IT revenues.
Industry Vertical Revenue Mix of Mastek (Q1 FY2027)
Mastek organizes its commercial client operations across Government, Health & Life Sciences, Retail & Financial Services end-markets.
- Government & Public Sector Share – 44.0% of Total Revenue
- Health & Life Sciences Share – 22.5% of Total Revenue
- Retail, Consumer & Logistics Share – 18.5% of Total Revenue
- Financial Services & Manufacturing Share – 15.0% of Total Revenue
Public sector government frameworks generate over four-tenths of total revenue, ensuring trade volume stability across multi-year modernization programs. Health and life sciences verticals provide steady enterprise software maintenance demand.
IT Industry KPIs & Operational Metrics of Mastek (Q1 FY2027)
Mastek tracks active client counts, employee headcounts, offshore delivery ratios, utilization rates, and voluntary attrition.
- Total Active Corporate Clients Base – 450+ enterprise clients
- Total Employee Headcount Base – 5,600+ IT & software professionals
- IT Service Personnel Utilization Rate – 78.5% utilization
- Trailing 12-Month Voluntary Attrition Rate – 12.8% (vs 13.5% in Q1 FY2026)
- Offshore vs Onshore Delivery Mix Share – Offshore: 68.0% / Onshore: 32.0%
- Million-Dollar Client Roster Scale – 52 clients generating over USD 1 million in annual revenue
Managing a talent pool of 5,600+ software professionals enables concurrent delivery of digital engineering projects globally. Maintaining a 78.5% utilization rate supports operational profit margins.
Executable Order Book & Deal Inflows of Mastek (Q1 FY2027)
The company maintains a 12-month executable order book providing revenue visibility across public sector and commercial client accounts.
- 12-Month Executable Order Backlog – Rs 1,880.50 crore (USD 225.0+ million)
- Order Backlog Expansion Rate – +15.2% YoY growth in constant currency terms
- Large Contract Wins Realised (Q1 FY2027) – Secured USD 45 million in new public sector contract awards
An executable order book backlog reaching Rs 1,880.50 crore provides top-line execution visibility across upcoming quarters. Securing USD 45 million in new public sector contract awards during Q1 FY2027 reinforces order replenishment momentum.
Latest Quarterly Financial Performance of Mastek (Q1 FY2027)
Mastek recorded double-digit top-line turnover expansion and net profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 820.50 crore (+12.4% YoY vs Rs 730.00 crore in Q1 FY2026)
- Consolidated Operating EBITDA – Rs 132.80 crore (+14.5% YoY vs Rs 116.00 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 16.19% (+30 bps YoY vs 15.89%)
- Consolidated Net Profit After Tax (PAT) – Rs 78.40 crore (+18.2% YoY vs Rs 66.30 crore in Q1 FY2026)
- Standalone Net Profit After Tax (PAT) – Rs 74.20 crore
First-quarter consolidated operating revenue expanded 12.4% year-on-year to Rs 820.50 crore, supported by UK public sector digital dispatches. Consolidated Net Profit After Tax reached Rs 78.40 crore, while operating EBITDA margins expanded to 16.19%.
Consolidated Annual Financial Performance of Mastek (FY2026)
The enterprise achieved full-year turnover growth and cash flow conversion during full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 3,180.40 crore (+14.8% YoY)
- Full Year Consolidated Operating EBITDA – Rs 512.20 crore (+16.2% YoY)
- Full Year Operating EBITDA Margin – 16.10% (+20 bps YoY)
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 305.80 crore (+19.5% YoY)
- Return on Capital Employed (ROCE) Realisation – 19.80%
- Return on Equity (ROE) Realisation – 16.50%
Full-year operating turnover crossed Rs 3,180.00 crore in FY2026, as consolidated Net Profit After Tax expanded 19.5% to Rs 305.80 crore. Delivering a return on capital employed of 19.80% reflects operating leverage across global delivery centers.
Balance Sheet Structure & Financial Health Ratios of Mastek (Q1 FY2027)
Mastek operates a net-cash balance sheet supported by equity net worth, liquid cash reserves, and low financial leverage.
- Financial Debt Status – Net Debt-Free / Net Cash Surplus
- Cash, Bank Balances & Liquid Treasury Reserves – ~Rs 520.00 crore
- Total Consolidated Shareholder Equity Net Worth Base – ~Rs 1,850.00 crore
- Days Sales Outstanding (DSO) – 78 days
- Credit Rating Profile – Reaffirmed '[CRISIL] AA- (Stable)' / 'CARE AA- (Stable)'
Operating a net debt-free balance sheet with ~Rs 520.00 crore in liquid treasury reserves provides capital independence. Reaffirming credit ratings at '[CRISIL] AA- (Stable)' confirms financial stability.
Generative AI Integration & M&A Roadmap of Mastek (FY2027–FY2028)
The enterprise executes a structured capital allocation strategy to commercialize generative AI frameworks and pursue tuck-in M&A acquisitions.
- GenAI Platform Framework – 'icxPro' Generative AI platform for enterprise customer experience
- Strategic Acquisition Integration – Integration of Biznet Solutions and MST Solutions (Oracle & Salesforce platforms)
- Annual R&D Outlay Guidance – Rs 50.00 to Rs 70.00 crore per annum for AI and spatial technology development
- Target Acquisition Geographies – US and European digital engineering and cloud consultancies
- Funding Strategy – 100% funded through internal operational cash accruals
Developing the proprietary 'icxPro' GenAI platform enables automated customer experience integrations for global enterprise accounts. Allocating Rs 50–70 crore per annum for R&D supports software capability additions in cloud engineering and spatial data.
Strategic Outlook & Management Commentary of Mastek (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on double-digit top-line growth, US market scaling, and margin preservation.
- Management targets maintaining a 12.0% to 15.0% annual top-line revenue growth rate in constant currency terms for FY2027.
- Consolidated operating EBITDA margins are guided to sustain between the 16.0% and 17.0% corridor.
- US revenue contribution share is targeted to expand toward 30.0% of total revenue through enterprise sales additions.
- UK public sector framework renewals will remain a key growth anchor across healthcare and government verticals.
- Generative AI solutions will be embedded across all core Oracle Cloud and digital engineering service offerings.
- Capital allocation strategy will prioritize self-funded tuck-in acquisitions while maintaining a net debt-free balance sheet.
Management anticipates strong UK public sector spending and US healthcare digital adoption to support full-year turnover targets. Operational focus centers on expanding US sales corridors, commercializing GenAI tools, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Mastek Limited Q1 FY2027 Unaudited Financial Disclosures & Board Outcomes
- Mastek Limited Investor Presentation & Performance Summary
- Stock Exchange Outcomes & Corporate Filings for Mastek Limited
- BSE Limited & National Stock Exchange of India (NSE) Disclosures for Mastek Limited
- Ticker Finology Mastek Limited Page
Disclaimer
The information presented above on Mastek Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Mastek Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.